Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
← catalyst calendarSponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
245estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-01 | actual | When the study began enrolling |
| Primary completion | Aug 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2023-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-09-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Glaucoma
Intervention
- Device: iStent Infinite
Primary outcome
what the primary-completion date above is the date OFMean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline
measured 12 Months
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed